Objectives This study sought to evaluate the long-term safety of the zotarolimus-eluting stent (ZES) using a pooled analysis of pivotal trials.
The treatment of coronary artery obstruction with percutaneous placement of coronary stents is associated with relief of anginal symptoms and infrequent late complications, yet the effectiveness of bare-metal stents (BMS) is limited by intimal hyperplasia and recurrent narrowing of the vessel in some patients. Approximately 14% of subjects treated with BMS require repeat percutaneous or surgical revascularization procedures to treat restenosis (1) . Several DES have been introduced over the past 7 years, following randomized clinical studies demonstrating their effectiveness at preventing restenosis within the first year (2) (3) (4) (5) . However, follow-up of patients in these studies has raised concerns regarding the safety of these stents beyond 1 year (6,7). Furthermore, it has become evident that single studies have lacked sufficient power to ascertain rare events such as late stent thrombosis (8) .
Pooled analysis of multiple studies and implementation of hierarchical case definitions of adverse events have been important to help understand the relative safety of the sirolimus and paclitaxel drug-eluting stents (DES) (8 -10) . Thrombosis rates from pooled studies of these stents, conducted after their approval by U.S. Food and Drug Administration (FDA) in 2003, have been reported previously, including data from approximately 800 patients at 4 years follow-up per DES type (8, 10 ) that showed no significant difference in rates of cardiac death or myocardial infarction but a greater number of stent thromboses occurring after the first year in the DES type compared with their respective BMS control subjects. The FDA has since approved additional DES with new metal scaffold materials and different polymers and antiproliferative medications (5, 11) . The agency approved the zotarolimus DES (Endeavor, Medtronic Cardiovascular, Santa Rosa, California) in 2008. The stent consists of a cobalt chromium stent scaffold, a phosphorylcholine polymer, and an antiproliferative rapamycin analogue, zotarolimus. The largest randomized trial of this stent compared it to the paclitaxel-eluting stent and showed noninferiority of the composite of cardiac death, target vessel reintervention, and myocardial infarction at 9 months (11) . In a randomized trial where the stent was compared with BMS, superiority of the zotarolimuseluting stent (ZES) was shown regarding target vessel reintervention (2) . These trials were part of a series of single arm and randomized trials of the same stent designed for FDA evaluation, all designed with uniform definitions, and prospective 5-year follow-up.
We conducted the current study as a pooled patient-level analysis of these studies to determine the safety of this new DES in long-term follow-up. We sought to increase the power to detect rare adverse events such as stent thrombosis by combining multiple individual studies and by employing uniform case definitions. The pooled data are continuously updated with results from each contributing trial to monitor the safety of this approved device. We compared rates of stent thrombosis, death, and myocardial infarction for the ZES to an identical stent lacking the drug and polymer in the same studies, after adjusting for between-study and -patient variation.
Methods
Study design. We pooled the latest available data on clinical safety outcomes from 6 prospective, multicenter, randomized, and single-arm trials evaluating the ZES. Long-term outcomes following placement of the ZES versus the BMS were compared after adjustment for between-trial variation and for individual patient clinical and angiographic characteristics by propensity score. Study population. The study population includes subjects enrolled in 6 trials designed as DES registration studies: 3 single arm studies-ENDEAVOR I (Multicenter Evaluation of ABT-578 Elution From a PhosphorylcholineCoated Stent) (12, 13) (11, 18) trials (1,548 subjects, compared against Taxus Express (Boston Scientific, Natick, Massachusetts). Trials included had uniform inclusion/exclusion criteria, end point definitions, adjudication, and follow-up procedures. Eligible subjects received treatment of single, previously untreated coronary lesions, as previously described. Patients were prescribed aspirin indefinitely and clopidogrel for a minimum of 3 months in all studies with the exception of 1 randomized study (19) where all patients were prescribed a minimum of 6 months of clopidogrel to maintain blinding and consistency with the instructions for use of the control paclitaxel-eluting stent. All studies were designed with uniform end point definitions, and all patients consented for 5 years of follow-up. Safety end points. The following safety end points were analyzed: death, cardiac death, myocardial infarction, cardiac death or myocardial infarction, and stent thrombosis. In the study protocols, stent thrombosis was defined as angiographic thrombus or subacute closure within the stented vessel at the time of the clinically driven angiographic restudy for documented ischemia (chest pain and electrocardiogram changes), and any death not attributed to a noncardiac cause within the first 30 days was considered a surrogate for stent thrombosis in the absence of documented angiographic stent patency. During the course of these studies, the Academic Research Consortium (ARC) (20) developed a uniform and hierarchical classification system for stent thrombosis, and the FDA recommended use of this classification system. Definite stent thrombosis required the presence of an acute coronary syndrome with angiographic or autopsy evidence of thrombus or occlusion. Probable stent thrombosis included unexplained deaths within 30 days after the procedure or acute myocardial infarction involving the target-vessel territory without angiographic confirmation. All events were adjudicated by an independent clinical events committee using both the original protocol definition and the ARC definitions of stent thrombosis. Additionally, the cumulative incidence of ARC definite and probable stent thrombosis was assessed by time interval: early (0 to 30 days), late (31 to 360 days), very late (Ͼ360 days). Statistical analysis. Descriptive statistics were calculated according to treatment for patient demographic, baseline clinical characteristics, and use of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel or ticlopidine through 5 years.
Patients who did not experience the end point in question who pre-maturely withdrew from the study or who had not yet reached the 5-year visit at the time of this analysis were censored at the time of last known follow-up. The proportional-hazards assumption for each treatment was assessed using the Kolmogorov-type supremum test (21) . Kaplan-Meier estimates of the cumulative incidence of outcomes are presented with 2-sided 95% confidence intervals for each treatment. For each end point, treatment groups were compared on time-to-event using Cox proportional hazards regression adjusting for the following baseline characteristics of age, sex, angiographic follow-up assignment, history of smoking, prior percutaneous coronary intervention, history of hyperlipidemia, prior myocardial infarction, prior coronary artery bypass grafting, worst angina category (stable, unstable, and myocardial infarction), race (white vs. nonwhite), number of diseased vessels, ejection fraction, vessel location, lesion location (proximal, mid, and distal), calcification, TIMI (Thrombolysis In Myocardial Infarction) flow grade, American College of Cardiology/American Heart Association lesion class B2 or C, reference vessel diameter, minimal lumen diameter, and lesion length, through the use of propensity scores. A propensity score (22) , calculated for each patient, is the probability that the patient received ZES or BMS as predicted by the patient's covariates. This predicted probability was calculated using logistic regression with treatment group (ZES vs. BMS) as the outcome and the covariates as the predictors. For any covariates with missing data, those missing values were replaced with the treatment-and sex-specific mean (for continuous outcomes) and treatmentand sex-specific median (for categorical outcomes) before creating the propensity score. Patients were then placed into nontreatment-specific quintiles according to their propensity score. Patients within the same quintiles generally are considered as having similar distributions of the covariates. The hazard ratio (DES vs. BMS), its 2-sided 95% confidence interval, and a 2-sided test of its significance adjusted for propensity score quintile are presented for each end point. As a secondary analysis for the composite end point of cardiac death or myocardial infarction and for the end point of ARC definite or probable stent thrombosis, we repeated the propensity-adjusted Cox proportional hazards regression and recalculated the hazard ratio and confidence interval, adding use of DAPT during the study as a time-dependent covariate.
The statistical analyses were performed using SAS software (version 9.1, SAS Institute, Inc., Cary, North Carolina).
Results
Patient characteristics. The analysis cohort included 2,132 patients treated with ZES and 596 patients treated with a BMS of the same design ( Fig. 1) (Table 1) (23, 24) . The median duration of follow-up was 4.01 years in the ZES group and 5.06 years in the BMS group. Five-year follow-up has been completed in 674 patients (97% of those eligible) and 582 patients (98%), respectively.
Across treatment groups, most patient and lesion characteristics were similar (Table 2 ) with a mean referencevessel diameter of 2.7 mm and mean lesion length of 14 mm. A history of diabetes mellitus, smoking, prior percutaneous coronary intervention, and triple-vessel coronary artery disease were exceptions and were more common in ZES-treated patients. The average ejection fraction was also noted to be lower in ZES-treated patients. Clinical events. The 5-year cumulative incidence of death, cardiac death, and myocardial infarction were each similar across treatment groups (Figs. 2A to 2C) ( Table 3 ). The propensity-adjusted hazard ratios for each of these clinical event rates showed no difference between the zotarolimuseluting and BMS treatment groups for all clinical outcomes. These results did not differ using covariate adjustment in place of propensity score adjustment. The test of proportional hazards was Ͼ0.5 in each case indicating that the proportional hazards assumption was met. Stent thrombosis. According to the protocol definition or the ARC definite and probable definition, the cumulative incidence of stent thrombosis during 5 years of follow-up did not differ significantly between ZES and BMS (propensity score-adjusted hazard ratio: 0.38 by protocol definition, p ϭ 0.157; 0.50 by ARC definite and probable definition, p ϭ 0.21) (Figs. 2D and 2E, Table 4 ). The cumulative rate of ARC definite and probable stent thrombosis in ZES over 5 years and after 1 year and through 5 years of follow-up were numerically lower than in BMS (1-to 5-year rates: 0.2%, 95% confidence interval: 0.0%, 0.54% vs. 0.4%, 95% confidence interval: 0.0%, 0.92%). The test of proportional hazards was Ͼ0.7 for both definitions of stent thrombosis indicating that the proportional hazards assumption was met.
Among subjects with ARC definite and probable stent thrombosis, the rates of subsequent mortality and myocardial infarction were 23% (6 of 26) and 77% (20 of 26) overall and did not differ between ZES-and BMS-treated subjects (p ϭ 0.35). Target lesion revascularization. The cumulative incidence of target lesion revascularization during the 5-year follow-up period was 7.0% of patients with ZES versus 16.5% of patients with BMS (p Ͻ 0.001) (Fig. 2F) . A risk difference of Ϫ7.8% was observed within the first year of follow-up and was sustained (risk difference: Ϫ9.5%) at 5 years of follow-up. DAPT. Dual antiplatelet therapy with aspirin and clopidogrel or ticlopidine was recommended in all but 1 trial for a minimum duration of 3 months. To preserve blinding in the ENDEAVOR IV trial, which compared the ZES to the paclitaxel-eluting stent, DAPT was recommended for a minimum of 6 months. At 1 year, 39% of the ZES-treated patients and 28% of BMS-treated patients remained on DAPT (Table 5) . During years 4 and 5 of follow-up, the rates of DAPT use fell to Ͻ10% of subjects for both treatments.
Stent thrombosis and clinical events in ZES versus BMS after adjustment for patient characteristics and DAPT.
After adjustment for DAPT use, there was no difference between stent types on all end point comparisons. Specifically, for cardiac death and myocardial infarction, the hazard ratio was 0.76 (0.50 to 1.16, p ϭ 0.20), and for ARC definite or probable stent thrombosis, the hazard ratio was 0.50 (0.17 to 1.48, p ϭ 0.21).
Discussion
In the setting of treatment of coronary obstructions to relieve angina, BMS have been effective, but are limited by the occurrence of in-stent restenosis. Despite this limitation, the occurrence of life-threatening thrombosis was considered be quite rare, occurring at a rate of approximately Mauri et al.
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0.6% to 0.7% within the first 30 days after implantation, and less frequently thereafter (25, 26) .
Randomized studies comparing the first drug-eluting (sirolimus-and paclitaxel-eluting) stents to stainless steel BMS demonstrated sustained reductions in clinical restenosis rates, yet careful scrutiny revealed higher numbers of stent thrombosis events in DES occurring after the first year of follow-up (8, 10) . These results raised concerns regarding the long-term safety of DES and reinforced the idea that the low thrombosis rates observed in BMS remained the appropriate benchmark for evaluation of safety of new stents. The same studies also indicated that the number of patients required to ascertain rare but serious adverse events with any certainty is large and the duration of follow-up required is longer than 1 year.
For new coronary stent evaluation, of which 4 types are FDA-approved (3) (4) (5) 19) , the FDA has required pooled analysis of all data acquired to detect whether such rare adverse events are more frequent in comparison with BMS either at 1-year or at longer-term follow-up (27) . The analysis presented here is the result of ongoing monitoring of the clinical and stent thrombosis event rates for the ZES relative to a contemporary cobalt chromium BMS of the same structural design. We observed no significant difference in crude or adjusted rates of death, cardiac death, myocardial infarction, or stent thrombosis to 5 years of follow-up in ZES-treated patients compared with BMStreated patients. These findings are similar to prior pooled studies of randomized studies of other DES compared with BMS (8,10). However, in contradistinction to these studies of other DES, we did observe a smaller number of late stent thrombosis events in the zotarolimus-eluting versus BMS comparison.
Each DES differs according to stent platform, polymer, and drug type, and, therefore, DES cannot be considered a true "class" of therapeutic devices. Although they may be structurally similar, stents with different bioactive materials cannot readily be classified to have the same biological mechanism of action. In the case of the ZES represented in this study, the stent struts and polymer coating are relatively thinner than prior DES, which has been identified as a potential mechanism for lower rates of acute myocardial infarction due to side branch occlusion (28) . The polymer coating in this case is phosphorylcholine, and in broad clinical experience on non-DES, this coating has not been associated with an increased risk of either restenosis or stent thrombosis relative to noncoated BMS (29) . The drug zotarolimus is an analogue of sirolimus, and yet the elution kinetics of this stent is relatively more rapid than the sirolimus-eluting stent (30) . These basic differences in mechanism could explain the similar safety profile of the ZES when compared with BMS. Pre-clinical and detailed clinical studies of the biological response to these stents have shown earlier cellular coverage of these stents in pre-clinical studies (31, 32) and clinical intravascular ultrasound (33) and optical coherence tomography evaluation (34 -35) , as well as more physiological response to vasoreactive stimuli compared with prior DES (36, 37) .
It may be difficult to weigh the clinical impact of a rare but grave adverse event such as stent thrombosis relative to the more common but less acute presentation of in-stent restenosis (38, 39) . Quantitative comparison with a decision analytic model has identified that when comparing drugeluting with BMS a difference as small as 0.14% per year in absolute late stent thrombosis rates over a 4-year period is sufficient to negate the clinical benefit attributable to restenosis prevention (38) . In the current study, however, both stent thrombosis and restenosis were lower for the DES over the 5-year follow-up (although not significantly for stent thrombosis).
It is important to note that the conclusions of any analysis are limited by the design of the analysis. First, the analysis performed was not pre-specified but was requested for the evaluation of safety by the FDA. As such, there was no a priori definition of noninferiority for the comparison of ZES to BMS. In this setting, it is useful to focus on the upper and lower confidence limits rather than the p value alone. Furthermore, although the pooled data achieves a larger sample size of prospective adjudicated data than available elsewhere, the sample size required to show a stent thrombosis difference of 1% is 8,000 (40) . Second, although each trial had similar patient and lesion inclusion requirements and characteristics in the enrolled population, not all included trials were randomized. The analysis is based on Values are % or mean Ϯ SD.
BMS ϭ bare-metal stent(s); MI ϭ myocardial infarction; PCI ϭ percutaneous coronary intervention; RVD ϭ reference vessel diameter; ZES ϭ zotarolimus-eluting stent(s).
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Long-Term ZES Clinical Outcomes pooling multiple ZES arms, but a single BMS arm. Although we employed a hierarchical propensity adjusted model to adjust for the effects of patient, lesion, and trial characteristics; it is possible that there are unmeasured confounders that result in residual confounding. Third, the use of DAPT in these trials was predominantly 3-to CI ϭ confidence interval; other abbreviations as in Table 2 . 6-months duration as the trials pre-dated the current recommendations of the American Heart Association/ American College of Cardiology for 12 months of treatment after DES placement in patients who are not at high risk of bleeding (41) . Overall, in comparing the 2 treatment groups, because 1 trial compared 2 DES, the duration of antiplatelet therapy was on average longer at certain time points for ZES. However, after adjustment for DAPT, there was no significant difference in outcome attributable to stent type. Finally, this analysis was performed primarily in the setting of patient with single-vessel treatment. This is similar to previous reports of pooled randomized trials of other DES to examine stent thrombosis and benefits from a high quality of adjudicated data, but may be limited from the point of generalizability to higher risk patient populations (8) . Randomized studies are required for definitive determination of superior safety of different DES. Several trials are ongoing. Investigators in Denmark compared the sirolimuseluting stent to the ZES in a randomized trial that employed the public health system to acquire clinical data in follow-up (42) . In contrast to the ENDEAVOR III randomized study (14) , the rate of myocardial infarction in this study favored the sirolimus-eluting stent. That study, however, employed an unusual design, using administrative data rather than clinical follow-up to record myocardial infarction, which is 1 possible explanation for the discrepant results. A large trial that is prospectively designed to compare late stent thrombosis rates in the ZES compared with the sirolimus-eluting stent is currently underway (PROTECT [Placebo-Controlled Randomized Study of the Selective A 1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function] trial) (43) . This study, although randomized, is more broadly inclusive than the studies pooled in the current analysis and has enrolled a patient population including treatment of multivessel disease and acute myocardial infarction. The comparison of stent thrombosis rates at 3 years is pending follow-up.
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The novel aspect to the current analysis of safety of the ZES is that this is the largest and longest-term follow-up of detailed, prospective, adjudicated data on stent thrombosis that is compared in an adjusted fashion to a BMS, considered the benchmark for long-term safety of stents. In this pooled analysis of clinical trial data examining the long-term safety of the ZES, comparison to an analogous BMS with propensity score adjustment showed no increase in rates of stent thrombosis, adverse cardiac events, or mortality at 5 years of follow-up in the largest adjudicated dataset from registration trials of a DES. Prospectively designed randomized trials are required for definitive determination of safety compared with other DES. *The ENDEAVOR I trial did not include a 6-month ascertainment of DAPT usage. Six-month estimates are based, therefore, on the remaining 5 studies.
DAPT ϭ dual antiplatelet therapy; other abbreviations as in Tables 1, 2 
